CXCR4 and prostate carcinoma: Inhibition of CXCR4 by plerixafor (AMD3100) or CTE9908 significantly reduced bone metastasis in prostate cancer model mice [278], as the tumorigenic potential is largely regulated by the CXCR4 signaling pathway in prostate cancer cells [279].